Controlled-Release Selexipag Composition for Lower Peak-Related Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional immediate release formulations of Selexipag result in rapid absorption leading to high peak-trough fluctuations in plasma concentration, causing severe adverse events such as headache, nausea, and vomiting, particularly in fasting conditions, necessitating a controlled release formulation to reduce side effects.
Innovation Solution
A controlled release pharmaceutical composition of Selexipag or its active metabolite with a controlled release rate to achieve a mean or median Tmax of at least 2.5 hours for Selexipag and at least 4 hours for the active metabolite, using matrixing agents or coating layers to control the release, thereby reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional immediate release formulation is used, then rapid absorption and quick therapeutic effect are achieved, but high peak-trough fluctuations cause severe adverse events such as headache, nausea, and vomiting
Solution Approach 1:
The patent applies dynamic release control by using pH-sensitive polymers that change their release characteristics in response to changing gastrointestinal pH conditions. The formulation transitions from faster release in acidic stomach environment to controlled release in neutral intestinal environment, optimizing both absorption speed and reducing adverse events at different physiological locations.
Solution Approach 2:
The patent changes the release rate parameter by using polymers with different pH sensitivity characteristics. The formulation exploits pH parameter changes along the GI tract to modulate drug release, achieving rapid initial release followed by sustained release, thereby reducing peak-trough fluctuations while maintaining therapeutic efficacy.
2Object-affected harmful factors
If controlled release formulation is used to reduce side effects, then tolerability is improved, but device complexity increases due to matrixing agents or coating layers
Solution Approach 1:
The patent employs pH-sensitive polymers that serve multiple functions simultaneously: they act as release-controlling agents, provide enteric protection, and utilize the body's natural pH gradients without requiring additional complex mechanisms. This multi-functionality reduces formulation complexity while achieving controlled release and reduced side effects.
Solution Approach 2:
The formulation utilizes the body's own pH environment to drive the release mechanism. The pH-sensitive polymers automatically respond to pH changes in the GI tract, eliminating the need for external control mechanisms or complex dosing regimens. The system self-regulates release based on physiological conditions, simplifying the overall formulation design.
Data Source
AI summary
This invention provides a method for treating a pulmonary arterial hypertension with reduced incident of side effect using a controlled release pharmaceutical composition of selexipag or its active metabolite, wherein the controlled release pharmaceutical composition of selexipag or its active metabolite following oral administration with an alcoholic beverage reduces incidence of at least one side effect associated with the selexipag or its active metabolite compared to the immediate-release dosage form comprising the same amount of the selexipag or active metabolite thereof.